Google
LKFT — LAKEFRONT BIOTHERAPEUTICS NV (Healthcare >> Biotechnology)
LKFT FAQ
What is LKFT's P/E ratio?
LAKEFRONT BIOTHERAPEUTICS NV (LKFT) currently trades at a P/E ratio of 2.29.
What is LKFT's ROE?
LAKEFRONT BIOTHERAPEUTICS NV reports a Return on Equity (ROE) of 15.02%.
What is LKFT's dividend yield?
LAKEFRONT BIOTHERAPEUTICS NV offers a dividend yield of 0.00%.
What is LKFT's Deepscope Quality Score?
Deepscope rates LKFT's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LKFT?
Deepscope's AI Timing Score for LKFT is 76 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LKFT belong to?
LAKEFRONT BIOTHERAPEUTICS NV is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 28.02
Price
-0.09
(-0.32%)
Day Change
|
|
|---|
LKFT, ファンダメンタルスコアはvery good ( ファンダメンタル = 85) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
平均ROEが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
63% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
168
|
| Magic Formula Rank by ROE |
168
|
| Magic Formula Rank by ROIC |
54
GOOD
|
| Price | 28.02 |
| PBV / Sector |
0.56 / 4.63
GREAT
|
| Earning Per Share | 7.50 |
| PE / Sector |
2.29 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
0.10 / 0.53
GREAT
|
| Average 1M Daily Value |
4.97 M
GREAT
|
| Average 1W Daily Value |
6.55 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
68% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:42 |
| Symbol | LKFT |
| Name | LAKEFRONT BIOTHERAPEUTICS NV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 65.90 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,825.35 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: SchaliEnhoevedreef 20 T, Mechelen, Belgium, 2800
Phone: 32 1 534 29 00
Website: https://lakefrontbio.com
Employees: -
Sector: Healthcare >> Biotechnology
Description: Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
